ZYMEWORKS INC. Capital Expenditures
ZYMEWORKS INC. (ZYME) reported Capital Expenditures of $216.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- ZYMEWORKS INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ZYMEWORKS INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $216.00K, a 1250.00% increase year-over-year.
- ZYMEWORKS INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $581.00K, a 85.03% increase year-over-year.
- ZYMEWORKS INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $410.00K, a 54.39% decline year-over-year.
- ZYMEWORKS INC. payments to acquire property, plant, and equipment for fiscal 2025 was $1.52M, a 23.61% decline from fiscal 2024.
- ZYMEWORKS INC. payments to acquire property, plant, and equipment for fiscal 2024 was $1.99M, a 19.52% decline from fiscal 2023.
- ZYMEWORKS INC. payments to acquire property, plant, and equipment for fiscal 2023 was $2.47M, a 69.64% decline from fiscal 2022.
- ZYMEWORKS INC. payments to acquire property, plant, and equipment for fiscal 2022 was $8.15M, a 34.30% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $216.00K 10-Q · filed 2026-08-06 | $797.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $216.00K 10-Q · filed 2026-05-07 | $797.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.21M derived: sum of 3 quarters · filed 2026-05-07 | $1.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $581.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $991.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.50M derived: sum of 3 quarters · filed 2026-08-06 | $1.52M 10-K · filed 2026-03-02 |
| 2025-09-30 | $410.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $924.00K derived: sum of 2 quarters · filed 2026-08-06 | $940.00K 10-Q · filed 2025-11-06 | $1.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $514.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $530.00K 10-Q · filed 2026-08-06 | $844.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $16.00K 10-Q · filed 2026-05-07 | $330.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.23M derived: sum of 3 quarters · filed 2026-05-07 | $1.82M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $314.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.21M derived: sum of 2 quarters · filed 2026-03-02 | $1.81M derived: sum of 3 quarters · filed 2026-03-02 | $1.99M 10-K · filed 2026-03-02 |
| 2024-09-30 | $899.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.49M derived: sum of 2 quarters · filed 2025-11-06 | $1.68M 10-Q · filed 2025-11-06 | $2.03M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $593.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $778.00K 10-Q · filed 2025-08-07 | $1.13M derived: sum of 3 quarters · filed 2026-03-02 | $2.06M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $185.00K 10-Q · filed 2025-05-08 | $541.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.47M derived: sum of 3 quarters · filed 2026-03-02 | $2.27M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.29M derived: sum of 2 quarters · filed 2026-03-02 | $2.09M derived: sum of 3 quarters · filed 2026-03-02 | $2.47M 10-K · filed 2026-03-02 |
| 2023-09-30 | $930.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $1.73M derived: sum of 2 quarters · filed 2024-10-31 | $2.12M 10-Q · filed 2024-10-31 | $2.47M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | $802.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $1.19M 10-Q · filed 2024-08-01 | $1.54M derived: sum of 3 quarters · filed 2025-03-05 | $2.52M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $386.00K 10-Q · filed 2024-05-02 | $734.00K derived: sum of 2 quarters · filed 2025-03-05 | $1.72M derived: sum of 3 quarters · filed 2025-03-05 | $4.38M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $348.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $1.33M derived: sum of 2 quarters · filed 2025-03-05 | $3.99M derived: sum of 3 quarters · filed 2025-03-05 | $8.15M 10-K · filed 2025-03-05 |
| 2022-09-30 | $981.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.64M derived: sum of 2 quarters · filed 2023-11-07 | $7.80M 10-Q · filed 2023-11-07 | $12.59M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $6.82M 10-Q · filed 2023-08-10 | $11.60M derived: sum of 3 quarters · filed 2024-03-06 | |
| 2022-03-31 | $4.16M 10-Q · filed 2023-05-08 | $8.94M derived: sum of 2 quarters · filed 2024-03-06 | ||
| 2021-12-31 | $4.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $12.40M 10-K · filed 2024-03-06 | ||
| 2021-09-30 | $7.62M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $4.31M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |